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Graft-versus-host disease (GvHD) is a severe complication 
of allogeneic hematopoietic cell transplantation (HCT). 
Extracorporeal photopheresis (ECP) is considered to be 
a second-line treatment for steroid-refractory acute and 
chronic GvHD (a/cGvHD) [1].
Several modifications of the conventional ECP appro-
ach have been developed, including ECP-treated enriched 
or depleted cell populations, ECP-treated allogeneic cells, 
cryopreservation of ECP-treated cells, and mini-ECP [2, 3]. 
The use of conventional ECP can be particularly challen-
ging for very young children with low body weight because 
of limited extracorporeal volume, difficulty in maintaining 
intravascular fluid balance, lack of adequate vascular ac-
cess, and the patient’s inability to tolerate the lengthy 
procedure [4].
Response to ECP was definied as:
 ■ a complete response (CR) if GvHD signs in all organs 
resolved;
 ■ a partial response (PR) if greater than 50% resolu-
tion was reached without other, additional immuno-
suppression;
 ■ no response if patients did not improve or required ad-
ditional immunosuppressive agents.
Response is usually assessed one and three months 
after the start of ECP. ECP is usually discontinued in pa-
tients who attain a CR or a steroid dose below 0.5 mg/kg 
body weight, or if patients have a lack of response or de-
velop progression to aGVHD [1].
The objective of this report was to present the feasi-
bility and safety of ECP in a one-year-old child with a body 
weight of 8.5 kg.
A 10-month-old boy with severe congenital neutropenia 
with ELANE gene mutation had HCT from a female matched 
unrelated donor, AB0/Rh compatible blood group, after con-
ditioning with busulfan (4 ×5.1 mg/kg/day, from –5 to –2), 
fludarabine (4 ×40 mg/m2/day, from –5 to –2), and rabbit 
thymoglobuline (4 × 2.5 mg/kg bw/day, from –5 to –2). 
Bone marrow was transplanted with 4.53 ×106 CD34 cells/ 
/kg. For GvHD prophylaxis, the patient was administered 
with cyclosporine and mycofenolate mofetil.
After five days, the patient received rituximab for pro-
phylaxis of post-transplant lymphoproliferative disorder [5]. 
He developed skin hyperacute aGvHD IV° in the first week 
after HCT, treated with methylprednisolone 2 mg/kg 
body weight, and steroid resistance was observed. After 
10 days, mesenchymal stem cells (MSC) were administe-
red with good response and complete resolution of skin 
changes. Cyclosporine doses were adjusted to keep his 
blood trough concentration close to 200 ng/mL, and stero-
id administration was gradually withdrawn. Neutrophil re-
covery occurred after 23 days, and platelet recovery after 
12 days. The donor chimerism on day +30 was 99%. After 
28 days, the skin symptoms of aGvHD had recurred, and 
GvHD of the gastrointestinal tract (GI) was suspected. 
Again, the response to increased doses of steroids was 
poor. The baby was administered a second dose of MSC 
with significant improvement but an incomplete respon-
se. Moderate skin and GI symptoms persisted in spite of 
steroid administration. Meanwhile, symptoms of Cushing 
syndrome appeared, and therefore ECP treatment was 
started after 76 days.
We used ‘in-line’ ECP with CellEX Photopheresis System 
(Therakos UK Ltd., Mallinckrodt Pharmaceuticals Company, 
UK). Owing to the extremely low body weight of the patient, 
a blood prime procedure with AB0/Rh compatible packed 
red blood cells in a single needle mode was carried out 
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8-methoxypsoralen was injected directly into the treat-
ment bag. The cells were afterwards irradiated in the ul-
traviolet (UVA) photoactivation module, as required by the 
protocol. The UVA-irradiated cells were then infused back 
into the patient.
The total volume of irradiated cells was approximately 
120 mL, and this was infused slowly over 30 minutes to 
prevent fluid overload. At the end of the procedure, the 
patient’s fluid balance was positive, at 15% of total body 
blood volume (within the accepted protocol). The patient to-
lerated both the blood collection and infusion of irradiated 
(Figure 1A). After blood prime, we connected to the patient 
and switched into double needle mode with simultaneo-
us blood drawing and returning by double lumen inguinal 
venous catheter. The drawing/returning speed was set at 
5–10 mL/min.
As part of the treatment, 200 mL of the patient’s 
whole blood was processed. For anticoagulation, hepa-
rin was used. Eventually, the patient received approxi-
mately 75 units of heparin during each ECP procedure. 
During the whole collection procedure, the patient’s vital 
signs were monitored. The buffy coat was extracted and 
Figure 1. Extracorporeal photopheresis (ECP): A. ECP control monitor; B. Patient lymphocyte subpopulations before and after ECP
Parameter Before ECP 1 month after ECP 3 months after ECP 7 months after ECP
[%] In 1 µL [%] In 1 µL [%] In 1 µL [%] In 1 µL
White blood cells – 250 – 3,700 – 24,780 – 14,060
Lymphocytes 66.0 165 18.0 675 13.0 3,221 20.0 2,812
CD19 0.9 1 0.0 0 2.2 71 2.8 79
CD2 81.5 134 88.7 599 86.8 2,796 84.4 2,373
CD3 76.8 127 66.2 447 80.4 2,590 74.9 2,106
CD4 66.0 109 56.4 381 61.7 1,987 45.2 1,271
CD8 12.0 20 12.0 81 19.8 638 35.3 993
CD3+4+ 65.5 108 56.3 380 61.0 1,965 44.8 1,260
CD3+8+ 12.0 20 12.0 81 19.3 622 34.7 976
CD3-16+56+ 0.5 1 12.1 82 1.7 55 11.7 329
CD3-CD8+ 0.7 1 2.9 20 0.6 19 5.3 149
CD4/CD8 5.5 – 4.7 – 3.1 – 1.3 –
CD3+4+/CD3+8+ 5.5 – 4.4 – 3.2 – 1.3 –
A
B
Acta Haematologica Polonica 2021, vol. 52, no. 2
www.journals.viamedica.pl/acta_haematologica_polonica144
cells; no adverse events were observed. The overall time of 
the whole procedure from the first blood collection to the 
end of reinfusion of treated buffy coat to the patient was 
approximately 120 minutes.
Two cycles of ECP on consecutive days were perfor-
med. Due to bacteremia, subsequent cycles were postpo-
ned. Four weeks after ECP was performed, steroids were 
reduced to a dose of 0.5 mg/kg body weight. Lymphocyte 
subpopulations were slowly normalising (Figure 1B). We co-
uld not determine CR/PR of GvHD. However, the success of 
the procedure carried out shows that ECP is feasible and 
safe in a baby of 8 kg body weight.
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